Signal Transduction by the Philadelphia Chromosome-encoded BCR/ABL Oncoproteins: Therapeutic Implications for Chronic Myeloid Leukemia and Philadelphia-positive Acute Lymphoblastic Leukemia

References

• Karin, M. (1995). The regulation of AP-1 activity by mitogen-activated protein kinases, J. Biol., Chem., 270, 16483–16486.
   PubMed Web of Science ®Google Scholar
• Karin, M. and Hunter, T. (1995). Transcriptional control by protein phosphorylation: signal transmission from the cell surface to the nucleus, Current Biology, 5, 747–757.
   PubMed Web of Science ®Google Scholar
• Hunter, T. (1996). Tyrosine phosphorylation: past, present and future, Biochem. Soc. Trans., 24, 307–327.
   PubMed Web of Science ®Google Scholar
• Marshall, M. S. (1995). Ras target proteins in eukaryotic cells, FASEB J., 9, 1311–1318.
   PubMed Web of Science ®Google Scholar
• Pawson, T. (1995). Protein modules and signalling networks, Nature, 373, 573–580.
   PubMed Web of Science ®Google Scholar
• Pawson, T. and Scott, J. D. (1997). Signaling through scaffold, anchoring and adaptor proteins, Science, 278, 2075–2080.
   PubMed Web of Science ®Google Scholar
• Darnell, J. E. (1997). STATs and gene regulation, Science, 277, 1630–1635.
   PubMed Web of Science ®Google Scholar
• Salvesen, G. S. and Dixit, V. M. (1997). Caspases: intracellular signaling by proteolysis, Cell, 91, 443–446.
   PubMed Web of Science ®Google Scholar
• Reed, J. C. (1997). Cytochrome c: Can't live with it-can't live without it, Cell, 91, 559–562.
   PubMed Web of Science ®Google Scholar
• Yang, E. and Korsmeyer, S. J. (1996). Molecular thanatopsis: a discourse on the BCL2 family and cell death, Blood, 88, 386–401.
   PubMed Web of Science ®Google Scholar
• Jurgensmeier, J. M., Xie, Z., Devereaux, Q., Ellerby, L., Bredesden, D. and Reed, J. C. (1998). Bax directly induces release of cytochrome c from isolate mitochondria, Proc. Natl. Acad. Sci. USA, 95, 4997–5002.
   PubMed Web of Science ®Google Scholar
• Yang, J., Liu, X., Bhalla, K, Kim, C. N., Ibrado, A. M., Cai, J., Peng, T.-I., Jones, D. P. and Wang, X. (1997). Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked, Science, 275, 1129–1132.
   PubMed Web of Science ®Google Scholar
• Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S. and Wang, X. (1997). Cytochrome c and dATP-dependent formation of apaf-1/caspase 9 complex initiates an apoptotic protease cascade, Cell, 91, 479–489.
   PubMed Web of Science ®Google Scholar
• Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y. and Greenberg, M. E. (1997). Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery, Cell, 91, 231–241.
   PubMed Web of Science ®Google Scholar
• del Peso, L., Gonzalez-Garcia, M., Page, C., Herrera, R. and Nunez, G. (1997). Interleukin 3-induced phosphorylation of BAD through protein kinase Akt, Science, 278, 687–689.
   PubMed Web of Science ®Google Scholar
• Hemmings, B. A. (1997). Akt signaling: linking membrane events to life and death decisions, Science, 275, 665–668.
   PubMed Web of Science ®Google Scholar
• Zha, J., Harada, H., Yang, E., Jockel, J. and Korsmeyer, S. J. (1996). Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3, not Bcl-XL, Cell, 87, 619–628.
   PubMed Web of Science ®Google Scholar
• Sawyers, C. L., Denny, C. T. and Witte, O. N. (1991). Leukemia and the disruption of hematopoiesis, Cell, 64, 337–350.
   PubMed Web of Science ®Google Scholar
• Nowell, P. C. and Hungerford, D. A. (1960). A minute chromosome in human granulocytic leukemia, Science, 132, 1497–1502.
   Web of Science ®Google Scholar
• Rowley, J. D. (1973). A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining, Nature, 243, 290–293.
   PubMed Web of Science ®Google Scholar
• Daley, G. Q., van Etten, R. A. and Baltimore, D. (1990). Induction of chronic myelogenous leukemia in mice by the p210Bcr/Abl gene of the Philadelphia chromosome, Science, 247, 824–830.
   PubMed Web of Science ®Google Scholar
• Seeker-Walker, L. M., Clark, R., Hawkins, J. M., Martineau, M. and Moorman, A.V. (1997). Age distribution of good and poor risk chromosomal sub-groups among the first 1500 cases in the LRF UKCCG karyotype database in acute lymphoblastic leukemia, Brit. J. Haematol., 97 (Suppl 1), 45.
   Google Scholar
• Kurzrock, R. and Talpaz, M. (1991). The genetics of the Philadelphia chromosome. In: Haematological Oncology, edited by Burnett, A., Newland, A. and Keating, A. Vol. 1, pp. 79–110. Cambridge University Press.
   Google Scholar
• Secker-Walker, L.M., Prentice, H. G., Durrant, J., Richards, S., Hall, E. and Harrison, G. (1997). Cytogenetics adds independent prognostic information in adults with acute lymphoblestic leukemia on MRC trial UKALL XA, Brit. J. Haematol., 96, 601–610.
   PubMed Web of Science ®Google Scholar
• Westin, E. H., Wong-Staal, F., Gelmann, E. P., Dalla-Favera, R., Papas, T. S., Lautenberger, J. A., Eva, A., Reddy, E. P., Tronick, S. R., Aaronson, S. A. and Gallo, R. C. (1982). Expression of cellular homologues of retroviral onc genes in human hematopoietic cells, Proc. Natl. Acad. Sci. USA, 79, 2490–2494.
   PubMed Web of Science ®Google Scholar
• Tybulewicz, V. J. L., Crawford, C. E., Jackson, P. K., Bronson, R. T. and Mulligan, R. C., Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene, Cell, 65, 1153–1163.
   PubMed Web of Science ®Google Scholar
• Konopka, J. B., Watanabe, S. M. and Witte, O.N. (1984). An alteration of the human c-abl protein in K562 cells unmasks associated tyrosine kinase activity, Cell, 37, 1035–1042.
   PubMed Web of Science ®Google Scholar
• Sawyers, C. L., McLaughlin, J., Goga, A., Havlik, M. and Witte, O. N. (1994). The nuclear tyrosine kinase c-abl negatively regulates cell growth, Cell, 77, 121–131.
   PubMed Web of Science ®Google Scholar
• McWhirter, J. R. and Wang, J. Y.-J. (1991). Activation of tyrosine kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins, Molec. Cell. Biol, 11, 553–1565.
   Web of Science ®Google Scholar
• McWhirter, J. R. and Wang, J. Y.-J. (1993). An actinbinding function contributes to transformation by the Bcr-Ab1 oncoprotein of Philadelphia chromosome-positive human leukemia, EMBO J., 12, 1533–1546.
   PubMed Web of Science ®Google Scholar
• van Etten, R. A., Jackson, P. and Baltimore, D. (1989). The mouse type IV c-abl gene product is a nuclear protein and activation of transforming ability is associated with cytoplasmic localization, Cell, 58, 669–678.
   PubMed Web of Science ®Google Scholar
• Lugo, T. G., Pendergast, A. M., Muller, A. M. and Witte, O. N. (1990). Tyrosine kinase activity and transforming potency of bcr/abl oncogene products, Science, 247, 1079–1082.
   PubMed Web of Science ®Google Scholar
• Raitano, A. B., Whang, Y. E. and Sawyers, C. L. (1997). Signal transduction by wild-type and leukemogenic Abl proteins, Biochem. Biophys. Acta, 1333, 201–216.
   PubMed Web of Science ®Google Scholar
• Pendergast, A. M., Muller, A. J., Havlik, M. H., Maru, Y. and Witte, O. N. (1991). BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner, Cell, 66, 161–171.
   PubMed Web of Science ®Google Scholar
• Sawyers, C. L., McLaughlin, J. and Witte, O. N. (1995). Genetic requirement for ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene, J. Exp. Med., 181, 307–313.
   PubMed Web of Science ®Google Scholar
• Pendergast, A.M., Quilliam, L.A., Cripe, L.D., Bassing, C. H., Dai, Z., Li, N., Batzer, A., Rabun, K. M., Der, C. J., Schlessinger, J. and Gishizky, M. L. (1993). BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein, Cell, 75, 175–185.
   PubMed Web of Science ®Google Scholar
• Raitano, A. B., Halpern, J. R., Hambuch, T. M. and Sawyers, C. L. (1995). The Bcr-Abl leukemia oncogene activates Jun and requires Jim for transformation, Proc. Natl. Acad. Sci. USA, 92, 1746–11750.
   Web of Science ®Google Scholar
• Goga, A., McLaughlin, J., Afar, D. E. H., Saffran, D. C. and Witte, O. N. (1995). Alternative signals to RAS for hematopoietic transformation by the BCR/ABL oncogene, Cell, 82, 981–988.
   PubMed Web of Science ®Google Scholar
• Salgia, R., Uemura, N., Okuda, K., Li, J.-L., Pisick, E., Sattler, M., de Jong, R., Druker, B., Heisterkamp, P. N., Chen, L. B., Groffen, J. and Griffin, J. D. (1995). CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells, J. Biol. Chem., 270, 29145–29150.
   PubMed Web of Science ®Google Scholar
• Senechal, K., Halpern, J. and Sawyers, C. L. (1996). The CRKL adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogene, J. Biol. Chem., 271, 23255–23261.
   PubMed Web of Science ®Google Scholar
• Salgia, R., Brunkhorst, B., Pisick, E., Li, J. L., Lo, S. H., Chen, L. B. and Griffin, J. D. (1995). increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL, Oncogene, 11, 1149–1155.
   PubMed Web of Science ®Google Scholar
• Salgia, R., Li, J. L., Ewaniuk, D. S., Pear, W., Pisick, E., Burky, S. A., Ernst, T., Sattler, M., Chen, L. B. and Griffin, J. D. (1997). BCR/ABL induces multiple abnormalities of cytoskeletal function, J. Clin. Invest., 100, 46–57.
   PubMed Web of Science ®Google Scholar
• Verfaillie, C. M., McCarthy, J. B. and McGlave, P. B. (1992). Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adherence to the bone marrow components laminin and collagen type IV, J. Clin. Invest., 90,1232–1241.
   PubMed Web of Science ®Google Scholar
• Salgia, R., Pisick, E., Sattler, M., Li, J.-L., Uemura, N., Wong, W.-K., Burky, S. A., Hirai, H., Chen, L. B. and Griffin, J. D. (1996). P130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene, J. Biol. Chem., 271, 25198–25203.
   PubMed Web of Science ®Google Scholar
• Fisher, D. E. (1994). Apoptosis in cancer therapy: crossing the threshold, Cell, 78, 539–542.
   PubMed Web of Science ®Google Scholar
• McGahon, A., Bissonnette, R., Schmitt, M., Cotter, K. M., Green, D. R. and Cotter, T.G. (1994). Bcr/Abl maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death, Blood, 83, 1179–1187.
   PubMed Web of Science ®Google Scholar
• Bedi, A., Zehnbauer, B. A., Barber, J. P., Sharkis, S. J. and Jones, R J. (1994). Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia, Blood, 83, 2038–2044.
   PubMed Web of Science ®Google Scholar
• Amarantes-Mendes, G. P., Kim, C. N., Liu, L., Huang, Y., Perkins, C. L., Green, D. R. and Bhalla, K. (1998). Bcr/Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome c and activation of caspase-3, Blood, 91, 1700–1705.
   PubMed Web of Science ®Google Scholar
• Sanchez-Garcia, I. and Gruss, G. (1995). Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2, Proc. Natl. Acad. Sci. USA, 92, 5287–5291.
   PubMed Web of Science ®Google Scholar
• Nishii, K., Kabarowski, J. H. S., Gibbons, D. L., Griffiths, S. D., Titley, I., Wiedemann, L. M. and Greaves, M. F. (1996). ts Bcr/Abl kinase confers increased resistance to genotoxic damage via cell cycle block, Oncogene, 13, 2225–2234.
   PubMed Web of Science ®Google Scholar
• Riordan, F. A., Bravery, C. A., Mengubas, K., Ray, N., Borthwick, N. J., Akbar, A. N., Hart, S. M., Hoffbrand, A. V., Mehta, A. B. and Wickremasinghe, R. G. (1998). Herbimycin A accelerates the induction of apoptosis following etoposide treatment or γ-irradiation of bcr/abl-positive leukemia cells, Oncogene, 16, 533–1542.
   PubMed Web of Science ®Google Scholar
• de Jong, R., ten Hoeve, J., Heisterkamp, N. and Groffen, J. (1995). Crkl is complexed with tyrosine-phosphorylated cbl in Philadelphia-positive leukemia, J. Biol. Chem., 270, 21468–21471.
   PubMed Web of Science ®Google Scholar
• Sattler, M., Salgia, R., Okuda, K., Uemura, N., Durstin, M. A., Pisick, E., Li, J. L., Prasad, K. V. and Griffin, J. D. (1996). The proto-oncogene product p210CBL and the adaptor proteins CRKL and c-CRK link c-ABL, pl90BCR/ABL and p210BCR/ABL to the phosphatidylinositol 3′-kinase pathway, Oncogene, 12, 839–846.
   PubMed Web of Science ®Google Scholar
• Sattler, M., Salgia, R., Shrikande, G., Verma, S., Pisick, E., Prasad, K. V. S. and Griffin, J. D. (1997). Steel factor induces tyrosine phosphorylation of CRKL and binding of CRKL to a complex containing c-Kit, phosphatidylinositol 3-kinase and pl20CBL, J. Biol. Chem., 272, 10248–10253.
   PubMed Web of Science ®Google Scholar
• Skorski, T., Kanakaraj, P., Nieborowska-Skorska, M., Ratajczak, M. Z., Wen, S.-C., Zon, G., Gewirtz, A. M., Perussia, B. and Calabretta, B. (1995). Phosphatidylinositol 3-kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells, Blood, 86, 726–736.
   PubMed Web of Science ®Google Scholar
• Skorski, T., Bellacosa, A., Nieborowska-Skorska, M., Majewski, M., Martinez, R., Choi, J.K., Trotta, R., Wlodarski, P., Perrotti, D., Chan, T. O., Wasik, M. A., Tsichlis, P. N. and Calabretta, B. (1997). Transformation of hematopoietic cells by BCR-ABL requires activation of a PI-3 kinase/Akt-dependent pathway, EMBO J., 16, 6151–6161.
   PubMed Web of Science ®Google Scholar
• Okabe, M. and Uehara, M. (1993). New insight into oncoprotein-targetted antitumour effect: herbimycin A as an antagonist of protein tyrosine kinase against Ph1-positive leukemia cells, Leukemia and Lymphoma, 12, 41–49.
   PubMed Web of Science ®Google Scholar
• Okabe, M., Uehara, Y., Miyagishima, T., Itaya, T., Tanaka, M., Kuni-Eda, Y., Kurosawa, M. and Miyazaki, T. (1992). Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations; abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein p210bcr/abl and preferential inhibition of Ph1-positive leukemia cell growth, Blood, 80, 1330–338.
   PubMed Web of Science ®Google Scholar
• Okabe, M., Kawamura, K, Miyagishima, T., Itaya, T., Goodwin, D., Shoji, M., Vogler, W. R., Sakurada, K., Uehara, M. and Miyazaki, T. (1994). Effect of herbimycin A, an inhibitor of tyrosine kinase, on protein tyrosine kinase activity and phosphotyrosyl proteins of Ph1-positive cells, Leukemia Res., 18, 23–220.
   PubMed Web of Science ®Google Scholar
• Sato, S., Honma, Y., Hozumi, M., Hayashi, Y., Matsuo, Y., Shibata, K, Omura, S., Hino, K., Tomoyasu, S. and Tsuruoka, N. (1994). Effects of herbimycin A and its derivatives on growth and differentiation of Ph1-positive acute lymphoid leukemia cells, Leukemia Res., 18, 221–228.
   PubMed Web of Science ®Google Scholar
• Yuan, Z.M., Huang, Y., Ishiko, T., Kharbanda, S., Weichselbaum, R. and Kufe, D. (1997). Regulation of DNA damage-induced apoptosis by the c-Abl tyrosine kinase, Proc. Natl. Acad. Sci. USA, 94, 1437–1440.
   PubMed Web of Science ®Google Scholar
• Honma, Y., Okabe-Kado, J., Kasukabe, T., Hozumi, M., Kodama, H., Kajigaya, S., Suda, T. and Miura, Y. (1992). Herbimycin A, an inhibitor of tyrosine kinase, prolongs survival of mice innoculated with myeloid luekemia C1 cells with high expression of v-abl tyrosine kinase, Cancer Res., 52, 4017–4020.
   PubMed Web of Science ®Google Scholar
• Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J. and Lydon, N. B. (1996). Effects of a selective inhibitor of the abl tyrosine kinase on the growth of Bcr/Abl-positive cells, Nature Medicine, 2, 561–566.
   PubMed Web of Science ®Google Scholar
• Carroll, M., Ohno-Jones, S., Tamura, S., Buchdunger, E., Zimmermann, J., Lydon, N. B., Gilliland, D. G. and Druker, B. J. (1997). CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing bcr-abl, Tel-abl and Tel-PDGFR, Blood, 90, 4947–4952.
   PubMed Web of Science ®Google Scholar
• Deininger, M. W., Goldman, J. M., Lydon, N. and Melo, J. V. (1997). The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL- positive cells, Blood, 90, 3691–3698.
   PubMed Web of Science ®Google Scholar
• Mahon, F.-X., Belloc, F., Vianes, I., Barbot, C., Boiron, J. M., Cowen, D., Lacombe, F., Brizard, A., Bilhou-Nabera, C., Bernard, P., Broustet, A. and Reiffers, J. (1995). Specific antisense oligomer anti Bcr-Abl junctions in chronic myeloid leukemia; a cell cycle analysis and CFU-GM study, Leukemia and Lymphoma, 19, 423–429.
   PubMed Web of Science ®Google Scholar
• O'Brien, S. G., Kirkland, M. A., Melo, J. V., Rao, M. H., Davidson, R. J., McDonald, C. and Goldman, J. M. (1994). Antisense BCR- ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines, Leukemia, 8, 2156–2162.
   PubMed Web of Science ®Google Scholar
• Vaerman, J. L., Moureau, P., Deldime, F., Lewalle, P., Lammineur, C., Morschhauser, F. and Martiat, P. (1997). Antisense oligodeoxyribonucleotides suppress hematologic cell growth through stepwise release of deoxyribonucleotides, Blood, 90, 331–339.
   PubMed Web of Science ®Google Scholar
• Leopold, L. H., Shore, S. K. and Reddy, E. P. (1996). Multi-unit anti-BCR-ABL ribozyme therapy in chronic myelogenous leukemia, Leukemia and Lymphoma, 22, 365–373.
   PubMed Web of Science ®Google Scholar